Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Celgene Makes Alliances With Kyn, Obsidian After Bristol Buyout

Executive Summary

Just two weeks after agreeing on a merger with Bristol, Celgene is back at its own deal-making, signing cancer-focused R&D pacts with Kyn and Obsidian. Boehringer and Bioharmony collaborate on novel therapies for hospital-acquired infections, while Sanofi teams with Biomunex on bi- and multi-specific antibodies.

Advertisement

Related Content

Otsuka, Click ‘Digital Therapeutic’ Alliance Aims At Novel Depression Option
Spectrum Reshuffles Focus, Selling Seven Products To Aurobindo
Asia Deal Watch: Boost For Esperion's Cholesterol Candidate As Daiichi Brought On Board
Deal Watch: Sanofi Retains Options To Two Bispecifics While Exiting Antibody Pact With Regeneron
Bristol Values Celgene's Hematology, Immunology Portfolio At $74bn, But Does It Price In Risk?
Deal Watch: Gilead Signs Two Deals In Two Days To Increase R&D Emphasis
Tech Transfer Roundup: Roivant Taps Research Labs For New Gene Therapies
Finance Watch: Ascletis First Biotech To List Under New Hong Kong Rules, BeiGene Joins In
Roche Primes New Push Via Cipla For Avastin, Actemra In India
Cipla Cuts Down In-House Biosimilars Plans

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC124515

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel